{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:14:37Z","timestamp":1787508877773,"version":"build-2736575974"},"reference-count":57,"publisher":"Impact Journals, LLC","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"published-print":{"date-parts":[[2024,8,31]]},"DOI":"10.18632\/aging.206074","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T19:37:00Z","timestamp":1724355420000},"page":"11994-12007","source":"Crossref","is-referenced-by-count":4,"title":["Association between dipeptidyl peptidase-4 inhibitor use and risk of Parkinson\u2019s disease among patients with diabetes mellitus: a retrospective cohort study"],"prefix":"10.18632","volume":"16","author":[{"given":"Kuang-Hua","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Health Services Administration, China Medical University, Taichung 406040, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yih","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Surgery, E-Da Hospital, I-Shou University, Kaohsiung 82445, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo-Yan","family":"Gau","sequence":"additional","affiliation":[{"name":"School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tung-Han","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Health Services Administration, China Medical University, Taichung 406040, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Ying","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Chung Shan Medical University, Taichung 40201, Taiwan"},{"name":"Department of Pharmacy, Chung Shan Medical University Hospital, Taichung 40201, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JPD-130175","article-title":"Parkinson\u2019s disease--the debate on the clinical phenomenology, aetiology, pathology and pathogenesis.","volume":"3","author":"Brooks","year":"2013","journal-title":"J Parkinsons Dis"},{"key":"2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","article-title":"Epidemiology of Parkinson\u2019s disease.","volume":"5","author":"Breteler","year":"2006","journal-title":"Lancet Neurol"},{"key":"3","doi-asserted-by":"publisher","first-page":"1720621","DOI":"10.1155\/2016\/1720621","article-title":"Alpha-Synuclein in Parkinson\u2019s Disease: From Pathogenetic Dysfunction to Potential Clinical Application.","volume":"201","author":"Pu","year":"2016","journal-title":"Parkinsons Dis"},{"key":"4","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","article-title":"Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction.","volume":"1","author":"Ghiglieri","year":"2023","journal-title":"Cell Death Dis"},{"key":"5","doi-asserted-by":"publisher","first-page":"842","DOI":"10.2337\/dc06-2011","article-title":"Type 2 diabetes and the risk of Parkinson\u2019s disease.","volume":"3","author":"Tuomilehto","year":"2007","journal-title":"Diabetes Care"},{"key":"6","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1212\/WNL.0b013e3182553cc9","article-title":"Clinical features of Parkinson disease when onset of diabetes came first: A case-control study.","volume":"7","author":"Pezzoli","year":"2012","journal-title":"Neurology"},{"key":"7","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.2337\/dc10-1333","article-title":"Diabetes and the risk of developing Parkinson\u2019s disease in Denmark.","volume":"3","author":"Ritz","year":"2011","journal-title":"Diabetes Care"},{"key":"8","doi-asserted-by":"publisher","first-page":"e3549","DOI":"10.1097\/MD.0000000000003549","article-title":"Risk of Parkinson Disease in Diabetes Mellitus: An Updated Meta-Analysis of Population-Based Cohort Studies.","volume":"9","author":"Li","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"9","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.pneurobio.2016.10.001","article-title":"Insulin resistance and Parkinson\u2019s disease: A new target for disease modification?","volume":"145","author":"Foltynie","year":"2016","journal-title":"Prog Neurobiol"},{"key":"10","doi-asserted-by":"publisher","first-page":"e001370","DOI":"10.1136\/bmjdrc-2020-001370","article-title":"Association between metformin and neurodegenerative diseases of observational studies: systematic review and meta-analysis.","volume":"8","author":"Li","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/1756285613493469","article-title":"Targeting heat shock proteins to modulate \u03b1-synuclein toxicity.","volume":"7","author":"McLean","year":"2014","journal-title":"Ther Adv Neurol Disord"},{"key":"12","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1093\/jnen\/62.4.389","article-title":"Colocalization of tau and alpha-synuclein epitopes in Lewy bodies.","volume":"6","author":"Dickson","year":"2003","journal-title":"J Neuropathol Exp Neurol"},{"key":"13","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.expneurol.2010.06.017","article-title":"Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson\u2019s disease brains with and without dementia.","volume":"22","author":"Sidhu","year":"2010","journal-title":"Exp Neurol"},{"key":"14","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s004010000283","article-title":"Distinct isoforms of tau aggregated in neurons and glial cells in brains of patients with Pick\u2019s disease, corticobasal degeneration and progressive supranuclear palsy.","volume":"10","author":"McGeer","year":"2001","journal-title":"Acta Neuropathol"},{"key":"15","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s10072-012-1006-0","article-title":"Spatial patterns of the tau pathology in progressive supranuclear palsy.","volume":"3","author":"Cairns","year":"2013","journal-title":"Neurol Sci"},{"key":"16","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/s41574-020-0399-8","article-title":"Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus.","volume":"1","author":"Deacon","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"17","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.beem.2009.03.004","article-title":"Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).","volume":"2","author":"Gallwitz","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"18","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.neuropharm.2014.10.007","article-title":"Saxagliptin: a novel antiparkinsonian approach.","volume":"8","author":"Abdallah","year":"2015","journal-title":"Neuropharmacology"},{"key":"19","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.3390\/ijms23042388","article-title":"Neuroprotective Effects of the DPP4 Inhibitor Vildagliptin inandModels of Parkinson\u2019s Disease.","volume":"2","author":"Seo","year":"2022","journal-title":"Int J Mol Sci"},{"key":"20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.nbd.2011.12.043","article-title":"Sitagliptin increases tau phosphorylation in the hippocampus of rats with type 2 diabetes and in primary neuron cultures.","volume":"4","author":"Yoon","year":"2012","journal-title":"Neurobiol Dis"},{"key":"21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/CLEP.S196293","article-title":"Taiwan\u2019s National Health Insurance Research Database: past and future.","volume":"1","author":"Lai","year":"2019","journal-title":"Clin Epidemiol"},{"key":"22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.37796\/2211-8039.1013","article-title":"Longitudinal data of multimorbidity and polypharmacy in older adults in Taiwan from 2000 to 2013.","volume":"1","author":"Lin","year":"2020","journal-title":"Biomedicine (Taipei)"},{"key":"23","doi-asserted-by":"publisher","first-page":"711723","DOI":"10.3389\/fpubh.2021.711723","article-title":"Dipeptidyl Peptidase 4 Inhibitors Decrease the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis C Infection and Type 2 Diabetes Mellitus: A Nationwide Study in Taiwan.","volume":"9","author":"Lee","year":"2021","journal-title":"Front Public Health"},{"key":"24","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1111\/ejn.12088","article-title":"DPP4-inhibitor improves neuronal insulin receptor function, brain mitochondrial function and cognitive function in rats with insulin resistance induced by high-fat diet consumption.","volume":"3","author":"Chattipakorn","year":"2013","journal-title":"Eur J Neurosci"},{"key":"25","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/dom.12432","article-title":"Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline.","volume":"1","author":"Flatt","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"26","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/jnc.13087","article-title":"Neuroprotective effects of vildagliptin in rat rotenone Parkinson\u2019s disease model: role of RAGE-NF\u03baB and Nrf2-antioxidant signaling pathways.","volume":"13","author":"Safar","year":"2015","journal-title":"J Neurochem"},{"key":"27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2174\/1872214810999160628105549","article-title":"Parkinson\u2019s Disease, Diabetes and Cognitive Impairment.","volume":"1","author":"Politis","year":"2016","journal-title":"Recent Pat Endocr Metab Immune Drug Discov"},{"key":"28","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1124\/dmd.108.026088","article-title":"Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections.","volume":"3","author":"Kirby","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"29","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/bdd.662","article-title":"Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats.","volume":"3","author":"Greischel","year":"2009","journal-title":"Biopharm Drug Dispos"},{"key":"30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1463-1326.2010.01306.x","article-title":"Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review.","volume":"1","author":"Deacon","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"31","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.2337\/db12-1794","article-title":"DPP-4 inhibition and neuroprotection: do mechanisms matter?","volume":"6","author":"Shannon","year":"2013","journal-title":"Diabetes"},{"key":"32","doi-asserted-by":"publisher","first-page":"630968","DOI":"10.3389\/fcvm.2021.630968","article-title":"Updated Role of Neuropeptide Y in Nicotine-Induced Endothelial Dysfunction and Atherosclerosis.","volume":"8","author":"Lin","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"33","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1002\/mds.26734","article-title":"Reduced incidence of Parkinson\u2019s disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study.","volume":"3","author":"Ludvigsson","year":"2016","journal-title":"Mov Disord"},{"key":"34","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1093\/brain\/awaa262","article-title":"Diabetes medications and risk of Parkinson\u2019s disease: a cohort study of patients with diabetes.","volume":"14","author":"Foltynie","year":"2020","journal-title":"Brain"},{"key":"35","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1093\/brain\/awab015","article-title":"Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinson\u2019s disease.","volume":"14","author":"Lee","year":"2021","journal-title":"Brain"},{"key":"36","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1080\/01616412.2018.1474840","article-title":"Sitagliptin rescues memory deficits in Parkinsonian rats via upregulating BDNF to prevent neuron and dendritic spine loss.","volume":"4","author":"Ma","year":"2018","journal-title":"Neurol Res"},{"key":"37","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s10787-017-0331-6","article-title":"Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson\u2019s disease.","volume":"2","author":"El Sayed","year":"2017","journal-title":"Inflammopharmacology"},{"key":"38","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/jphp.12936","article-title":"Ineffectiveness of saxagliptin as a neuroprotective drug in 6-OHDA-lesioned rats.","volume":"7","author":"Vital","year":"2018","journal-title":"J Pharm Pharmacol"},{"key":"39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4137\/CMED.S5114","article-title":"Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus.","volume":"4","author":"Schwartz","year":"2011","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"40","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.2337\/diabetes.54.10.2988","article-title":"Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.","volume":"5","author":"Lyons","year":"2005","journal-title":"Diabetes"},{"key":"41","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1073\/pnas.88.4.1556","article-title":"Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function.","volume":"8","author":"Bachovchin","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"42","doi-asserted-by":"publisher","DOI":"10.1016\/s0041-1345(98)02069-7","article-title":"Specific inhibition of CD26\/DPP IV enzymatic activity in allograft recipients: effects on humoral immunity.","author":"Kupiec-Weglinski","year":"1999","journal-title":"Transplant Proc"},{"key":"43","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.vascn.2014.11.002","article-title":"Establishment of a dipeptidyl peptidases (DPP) 8\/9 expressing cell model for evaluating the selectivity of DPP4 inhibitors.","volume":"7","author":"Shen","year":"2015","journal-title":"J Pharmacol Toxicol Methods"},{"key":"44","doi-asserted-by":"publisher","first-page":"46","DOI":"10.4103\/ijp.IJP_384_20","article-title":"Neuroprotective effects of linagliptin in a rotenone-induced rat model of Parkinson\u2019s disease.","volume":"5","author":"Patel","year":"2022","journal-title":"Indian J Pharmacol"},{"key":"45","doi-asserted-by":"publisher","first-page":"6423","DOI":"10.1021\/acsomega.2c06634","article-title":"Linagliptin and Empagliflozin Inhibit Microtubule Affinity Regulatory Kinase 4: Repurposing Anti-Diabetic Drugs in Neurodegenerative Disorders UsingandApproaches.","volume":"8","author":"Shamsi","year":"2023","journal-title":"ACS Omega"},{"key":"46","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.4103\/1673-5374.360242","article-title":"Exendin-4 and linagliptin attenuate neuroinflammation in a mouse model of Parkinson\u2019s disease.","volume":"1","author":"Feng","year":"2023","journal-title":"Neural Regen Res"},{"key":"47","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1124\/dmd.112.048470","article-title":"Evaluation and prediction of potential drug-drug interactions of linagliptin usingcell culture methods.","volume":"4","author":"Schaefer","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"48","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s12640-019-9998-3","article-title":"Sitagliptin and Liraglutide Modulate L-dopa Effect and Attenuate Dyskinetic Movements in Rotenone-Lesioned Rats.","volume":"3","author":"El Sayed","year":"2019","journal-title":"Neurotox Res"},{"key":"49","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.physbeh.2018.01.028","article-title":"Linagliptin potentiates the effect of l-dopa on the behavioural, biochemical and immunohistochemical changes in experimentally-induced Parkinsonism: Role of toll-like receptor 4, TGF-\u03b21, NF-\u03baB and glucagon-like peptide 1.","volume":"18","author":"Alrobaian","year":"2018","journal-title":"Physiol Behav"},{"key":"50","doi-asserted-by":"publisher","first-page":"6542","DOI":"10.3390\/ijms23126542","article-title":"The Effectiveness of Antidiabetic Drugs in Treating Dementia: A Peek into Pharmacological and Pharmacokinetic Properties.","volume":"2","author":"Yamaguchi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"51","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.4103\/1673-5374.332122","article-title":"Parkinson\u2019s disease and diabetes mellitus: common mechanisms and treatment repurposing.","volume":"1","author":"Rodriguez-Perez","year":"2022","journal-title":"Neural Regen Res"},{"key":"52","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nrn3039","article-title":"Ageing as a primary risk factor for Parkinson\u2019s disease: evidence from studies of non-human primates.","volume":"1","author":"Kordower","year":"2011","journal-title":"Nat Rev Neurosci"},{"key":"53","doi-asserted-by":"publisher","first-page":"E7","DOI":"10.1152\/ajpendo.00366.2002","article-title":"Aging and insulin secretion.","volume":"28","author":"Halter","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"54","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/mds.25945","article-title":"The prevalence of Parkinson\u2019s disease: a systematic review and meta-analysis.","volume":"2","author":"Steeves","year":"2014","journal-title":"Mov Disord"},{"key":"55","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.1600-0404.2006.00579.x","article-title":"A systematic review of depression and mental illness preceding Parkinson\u2019s disease.","volume":"11","author":"Brayne","year":"2006","journal-title":"Acta Neurol Scand"},{"key":"56","doi-asserted-by":"publisher","first-page":"143547","DOI":"10.4061\/2011\/143547","article-title":"Neurobiology of depression and anxiety in Parkinson\u2019s disease.","volume":"201","author":"Iwasaki","year":"2011","journal-title":"Parkinsons Dis"},{"key":"57","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/S1474-4422(16)30230-7","article-title":"The epidemiology of Parkinson\u2019s disease: risk factors and prevention.","volume":"1","author":"Schwarzschild","year":"2016","journal-title":"Lancet Neurol"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.206074","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T23:52:14Z","timestamp":1725580334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.206074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":57,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024,8,31]]}},"alternative-id":["206074","39177655"],"URL":"https:\/\/doi.org\/10.18632\/aging.206074","relation":{},"ISSN":["1945-4589"],"issn-type":[{"value":"1945-4589","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,22]]}}}